Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q4 2017 · 10-K
Revenue$282.83K$282.83K−5.4% vs Q4 2016 Net Income-$8.03M-$8.03MN/M vs Q4 2016 EPS Diluted-$0.46-$0.46N/M vs Q4 2016 Operating Income-$8,092,960N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,770,703N/M Margins · derivedOperating margin-2861.4%−190.3 pt vs Q4 2016
Net margin-2838.7%−195.7 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 7, 2018 · 66 d after period end